

LOGINID:SSSPTA1642BJF

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 "Ask CAS" for self-help around the clock
NEWS 3 DEC 18 CA/CAPLUS pre-1967 chemical substance index entries enhanced
with preparation role
NEWS 4 DEC 18 CA/CAPLUS patent kind codes updated
NEWS 5 DEC 18 MARPAT to CA/CAPLUS accession number crossover limit increased
to 50,000
NEWS 6 DEC 18 MEDLINE updated in preparation for 2007 reload
NEWS 7 DEC 27 CA/CAPLUS enhanced with more pre-1907 records
NEWS 8 JAN 08 CHEMLIST enhanced with New Zealand Inventory of Chemicals
NEWS 9 JAN 16 CA/CAPLUS Company Name Thesaurus enhanced and reloaded
NEWS 10 JAN 16 IPC version 2007.01 thesaurus available on STN
NEWS 11 JAN 16 WPIDS/WPINDEX/WPIX enhanced with IPC 8 reclassification data
NEWS 12 JAN 22 CA/CAPLUS updated with revised CAS roles
NEWS 13 JAN 22 CA/CAPLUS enhanced with patent applications from India
NEWS 14 JAN 29 PHAR reloaded with new search and display fields
NEWS 15 JAN 29 CAS Registry Number crossover limit increased to 300,000 in
multiple databases
NEWS 16 FEB 15 PATDPASPC enhanced with Drug Approval numbers
NEWS 17 FEB 15 RUSSIAPAT enhanced with pre-1994 records
NEWS 18 FEB 23 KOREAPAT enhanced with IPC 8 features and functionality
NEWS 19 FEB 26 MEDLINE reloaded with enhancements
NEWS 20 FEB 26 EMBASE enhanced with Clinical Trial Number field
NEWS 21 FEB 26 TOXCENTER enhanced with reloaded MEDLINE
NEWS 22 FEB 26 IFICDB/IFIPAT/IFIUDB reloaded with enhancements
NEWS 23 FEB 26 CAS Registry Number crossover limit increased from 10,000
to 300,000 in multiple databases
NEWS 24 MAR 15 WPIDS/WPIX enhanced with new FRAGHITSTR display format
NEWS 25 MAR 16 CASREACT coverage extended
NEWS 26 MAR 20 MARPAT now updated daily
NEWS 27 MAR 22 LWPI reloaded
NEWS 28 MAR 30 RDISCLOSURE reloaded with enhancements
NEWS 29 MAR 30 INPADOCDB will replace INPADOC on STN
NEWS 30 APR 02 JICST-EPLUS removed from database clusters and STN

NEWS EXPRESS NOVEMBER 10 CURRENT WINDOWS VERSION IS V8.01c, CURRENT
MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 25 SEPTEMBER 2006.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items
NEWS IPC8 For general information regarding STN implementation of IPC 8
NEWS X25 X.25 communication option no longer available

Enter NEWS followed by the item number or name to see news on that
specific topic.

All use of STN is subject to the provisions of the STN Customer
agreement. Please note that this agreement limits use to scientific
research. Use for software development or design or implementation
of commercial gateways or other similar uses is prohibited and may
result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 12:51:41 ON 12 APR 2007

=> file reg
COST IN U.S. DOLLARS
FULL ESTIMATED COST

	SINCE FILE ENTRY	TOTAL SESSION
	0.21	0.21

FILE 'REGISTRY' ENTERED AT 12:51:46 ON 12 APR 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 11 APR 2007 HIGHEST RN 929721-97-1
DICTIONARY FILE UPDATES: 11 APR 2007 HIGHEST RN 929721-97-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=> E "CAPTOPRIL"/CN 25

E1	1	CAPTOPRDS/CN
E2	1	CAPTOPRESS/CN
E3	1	--> CAPTOPRIL/CN
E4	1	CAPTOPRIL DISULFIDE/CN
E5	1	CAPTOPRIL GLUTATHIONE DISULFIDE/CN
E6	1	CAPTOPRIL HYDROCHLORIDE/CN
E7	1	CAPTOPRIL METHYLTRANSFERASE/CN
E8	1	CAPTOPRIL THIOL METHYLTRANSFERASE/CN
E9	1	CAPTOPRIL TZ/CN
E10	1	CAPTOPRIL-FRUSEMIDE MIXT./CN
E11	1	CAPTOPRIL-HYDROCHLOROTHIAZIDE MIXT./CN
E12	1	CAPTOPRIL-KETANSERIN MIXT./CN
E13	1	CAPTOPRIL-THIAZIDE/CN
E14	1	CAPTOR/CN
E15	1	CAPTORIL/CN
E16	1	CAPTOSTIBONE/CN
E17	1	CAPTROL/CN
E18	2	CAPTURE/CN
E19	1	CAPTURE (PESTICIDE)/CN
E20	1	CAPTURE (POLYMER)/CN
E21	1	CAPTURE SPIRAL SILK PROTEIN (NEPHILA CLAVIPES FLAGELLIFORM GLAND C-TERMINAL FRAGMENT)/CN
E22	1	CAPTURE SPIRAL SILK PROTEIN (NEPHILA CLAVIPES FLAGELLIFORM GLAND PRECURSOR N-TERMINAL FRAGMENT)/CN
E23	1	CAPTURE WR 6/CN
E24	1	CAPTURE-DIMETHOATE MIXT./CN
E25	1	CAPTURE-ORTHENE MIXT./CN

=> S E3

L1 1 CAPTOPRIL/CN

=> E "LOSARTAN"/CN 25

E1	1	LOSAN/CN
E2	1	LOSANTIN/CN
E3	1 -->	LOSARTAN/CN
E4	1	LOSARTAN MONOPOTASSIUM SALT/CN
E5	1	LOSARTAN P-TOLUENESULFONATE/CN
E6	1	LOSARTAN POTASSIUM/CN
E7	1	LOSARTAN POTASSIUM SALT/CN
E8	1	LOSARTAN-HYDROCHLOROTHIAZIDE MIXT./CN
E9	1	LOSANINE/CN
E10	1	LOSE-URONATE KETOL-ISOMERASE (YERSINIA PESTIS STRAIN CO92 GENE
KDUI)/CN		
E11	1	LOSEC/CN
E12	1	LOSEC SODIUM/CN
E13	1	LOSEYITE/CN
E14	1	LOSFERRON/CN
E15	1	LOSIGAMONE/CN
E16	1	LOSIL 1000-50/CN
E17	1	LOSIL 1000-65/CN
E18	1	LOSIL 800-50/CN
E19	1	LOSIL 800-65/CN
E20	1	LOSINDOLE/CN
E21	1	LOSIUM/CN
E22	1	LOSK/CN
E23	1	LOSMIPROFEN/CN
E24	1	LOSO PREP/CN
E25	1	LOSOL BLUE/CN

=> S E3

L2 1 LOSARTAN/CN

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	10.35	10.56

FILE 'CAPLUS' ENTERED AT 12:52:31 ON 12 APR 2007
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 12 Apr 2007 VOL 146 ISS 16
 FILE LAST UPDATED: 11 Apr 2007 (20070411/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s 11/thu

5249 L1
 877695 THU/RL

L3 2324 L1/THU
 (L1 (L) THU/RL)

```
=> s 12/thu
      2711 L2
      877695 THU/RL
L4      1975 L2/THU
        (L2 (L) THU/RL)

=> s cancer? or neoplas? or tumor? or carcinom?
      327650 CANCER?
      488538 NEOPLAS?
      465070 TUMOR?
      166706 CARCINOM?
L5      788148 CANCER? OR NEOPLAS? OR TUMOR? OR CARCINOM?
```

```
=> s 13 (L) 15
L6      26 L3 (L) L5
```

```
=> s 16 not py>2000
      7043137 PY>2000
L7      8 L6 NOT PY>2000
```

```
=> s 17 and human
      1758388 HUMAN
      345672 HUMANS
      1926622 HUMAN
        (HUMAN OR HUMANS)
L8      4 L7 AND HUMAN
```

```
=> d ibib 1-4
```

```
L8 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1999:794097 CAPLUS <<LOGINID::20070412>>
DOCUMENT NUMBER: 132:18639
TITLE: Do ACE-inhibitors suppress tumor necrosis
factor- $\alpha$  production in advanced chronic renal
failure?
AUTHOR(S): Stenvinkel, P.; Andersson, P.; Wang, T.; Lindholm, B.;
Bergstrom, J.; Palmblad, J.; Heimbürger, O.;
Cederholm, T.
CORPORATE SOURCE: Departments of Clinical Science, Divisions of Renal
Medicine and Baxter Novum, Stockholm, Swed.
SOURCE: Journal of Internal Medicine (1999), 246(5), 503-507
CODEN: JINMEO; ISSN: 0954-6820
PUBLISHER: Blackwell Science Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English
REFERENCE COUNT: 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT
```

```
L8 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1999:473537 CAPLUS <<LOGINID::20070412>>
DOCUMENT NUMBER: 132:44577
TITLE: Influence of putative antiinvasive agents on matrix
metalloproteinase secretion by human
neoplastic glia in vitro
AUTHOR(S): Rooprai, H. K.; Kandaneeratachi, A.; Rucklidge, G.;
Pilkington, G. J.
CORPORATE SOURCE: Department of Neuropathology, Institute of Psychiatry,
London, SE5 8AF, UK
SOURCE: Annals of the New York Academy of Sciences (1999),
878(Inhibition of Matrix Metalloproteinases), 654-657
CODEN: ANYAA9; ISSN: 0077-8923
PUBLISHER: New York Academy of Sciences
DOCUMENT TYPE: Journal
```

LANGUAGE: English
REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1998:238843 CAPLUS <<LOGINID::20070412>>
DOCUMENT NUMBER: 128:317013
TITLE: Captopril inhibits tumor growth in a xenograft model
of human renal cell carcinoma
AUTHOR(S): Hii, S. -I.; Nicol, D. L.; Gotley, D. C.; Thompson, L.
C.; Green, M. K.; Jonsson, J. R.
CORPORATE SOURCE: Department of Surgery, Princess Alexandra Hospital,
University of Queensland, Woolloongabba, 4102,
Australia
SOURCE: British Journal of Cancer (1998), 77(6), 880-883
CODEN: BJCAAI; ISSN: 0007-0920
PUBLISHER: Churchill Livingstone
DOCUMENT TYPE: Journal
LANGUAGE: English
REFERENCE COUNT: 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1997:561786 CAPLUS <<LOGINID::20070412>>
DOCUMENT NUMBER: 127:229321
TITLE: Captopril modulates hormone receptor concentration and
inhibits proliferation of human mammary
ductal carcinoma cells in culture
AUTHOR(S): Small, William, Jr.; Molteni, Agostino; Kim, Yoon T.;
Taylor, Joann M.; Chen, Zehan; Ward, William F.
CORPORATE SOURCE: Department of Radiology, Northwestern University
Medical School, Chicago, IL, USA
SOURCE: Breast Cancer Research and Treatment (1997), 44(3),
217-224
CODEN: BCTRD6; ISSN: 0167-6806
PUBLISHER: Kluwer
DOCUMENT TYPE: Journal
LANGUAGE: English
REFERENCE COUNT: 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d his

(FILE 'HOME' ENTERED AT 12:51:41 ON 12 APR 2007)

FILE 'REGISTRY' ENTERED AT 12:51:46 ON 12 APR 2007

E "CAPTOPRIL"/CN 25
L1 1 S E3
E "LOSARTAN"/CN 25
L2 1 S E3

FILE 'CAPLUS' ENTERED AT 12:52:31 ON 12 APR 2007

L3 2324 S L1/THU
L4 1975 S L2/THU
L5 788148 S CANCER? OR NEOPLAS? OR TUMOR? OR CARCINOM?
L6 26 S L3 (L) L5
L7 8 S L6 NOT PY>2000
L8 4 S L7 AND HUMAN

=> s 14 (L) 15

L9 10 L4 (L) L5

=> d ibib 1-9

L9 ANSWER 1 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2006:182557 CAPLUS <<LOGINID::20070412>>
 DOCUMENT NUMBER: 144:267234
 TITLE: Effects of angiotensin II receptor antagonist,
 Losartan on the apoptosis, proliferation and migration
 of the human pancreatic stellate cells
 AUTHOR(S): Liu, Wen-Bin; Wang, Xing-Peng; Wu, Kai; Zhang, Ru-Ling
 CORPORATE SOURCE: Shanghai No. 1 People's Hospital, Shanghai Jiaotong
 University, Shanghai, 200080, Peop. Rep. China
 SOURCE: World Journal of Gastroenterology (2005), 11(41),
 6489-6494
 CODEN: WJGAF2; ISSN: 1007-9327
 PUBLISHER: World Journal of Gastroenterology
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 REFERENCE COUNT: 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 2 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2006:101964 CAPLUS <<LOGINID::20070412>>
 DOCUMENT NUMBER: 144:184652
 TITLE: Novel pathways in the etiology of cancer, and
 treatment methods
 INVENTOR(S): Benz, Christopher C.
 PATENT ASSIGNEE(S): Buck Institute for Age Research, USA
 SOURCE: U.S. Pat. Appl. Publ., 49 pp.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2006024691	A1	20060202	US 2005-90546	20050324
PRIORITY APPLN. INFO.:			US 2004-556774P	P 20040325
			US 2004-580534P	P 20040616
			US 2004-629691P	P 20041119

L9 ANSWER 3 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2005:1284893 CAPLUS <<LOGINID::20070412>>
 DOCUMENT NUMBER: 144:285876
 TITLE: TGF- β and TNF- α producing effects of
 losartan and amlodipine on human mononuclear cell
 culture
 AUTHOR(S): Kaynar, Kubra; Ulusoy, Sukru; Ovali, Ercument;
 Vanizor, Birgul; Dikmen, Tamer; Gul, Semih
 CORPORATE SOURCE: Department of Nephrology, School of Medicine,
 Karadeniz Technical University, Trabzon, Turk.
 SOURCE: Nephrology (2005), 10(5), 478-482
 CODEN: NEPHF2; ISSN: 1320-5358
 PUBLISHER: Blackwell Publishing Asia Pty Ltd.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 REFERENCE COUNT: 29 THERE ARE 29 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 4 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2005:1213085 CAPLUS <<LOGINID::20070412>>
 DOCUMENT NUMBER: 144:225211
 TITLE: G protein-coupled receptors as targets for drug
 discovery
 AUTHOR(S): Esbenshade, Timothy A.

CORPORATE SOURCE: Neuroscience Research, Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, IL, USA
SOURCE: Drug Discovery Series (2006), Volume 4, Issue G Protein-Coupled Receptors in Drug Discovery, 15-36. CRC Press LLC: Boca Raton, Fla.
CODEN: DDSRBS
DOCUMENT TYPE: Conference; General Review
LANGUAGE: English
REFERENCE COUNT: 73 THERE ARE 73 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 5 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2005:1188658 CAPLUS <<LOGINID::20070412>>
DOCUMENT NUMBER: 144:16589
TITLE: Antiproliferative activity of angiotensin II receptor blocker through cross-talk between stromal and epithelial prostate cancer cells
AUTHOR(S): Uemura, Hiroji; Ishiguro, Hitoshi; Nagashima, Yoji; Sasaki, Takeshi; Nakaigawa, Noboru; Hasumi, Hisashi; Kato, Shingo; Kubota, Yoshinobu
CORPORATE SOURCE: Department of Urology and Second Department of Pathology, Yokohama City University Graduate School of Medicine, Yokohama, Japan
SOURCE: Molecular Cancer Therapeutics (2005), 4(11), 1699-1709
CODEN: MCTOCF; ISSN: 1535-7163
PUBLISHER: American Association for Cancer Research
DOCUMENT TYPE: Journal
LANGUAGE: English
REFERENCE COUNT: 40 THERE ARE 40 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 6 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2005:291659 CAPLUS <<LOGINID::20070412>>
DOCUMENT NUMBER: 143:323408
TITLE: Blockage of angiotensin II type I receptor decreases the synthesis of growth factors and induces apoptosis in C6 cultured cells and C6 rat glioma
AUTHOR(S): Arrieta, O.; Guevara, P.; Escobar, E.; Garcia-Navarrete, R.; Pineda, B.; Sotelo, J.
CORPORATE SOURCE: Neuroimmunology Unit of the National Institute of Neurology and Neurosurgery of Mexico, Mexico City, 14269, Mex.
SOURCE: British Journal of Cancer (2005), 92(7), 1247-1252
CODEN: BJCAAI; ISSN: 0007-0920
PUBLISHER: Nature Publishing Group
DOCUMENT TYPE: Journal
LANGUAGE: English
REFERENCE COUNT: 55 THERE ARE 55 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 7 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2003:862779 CAPLUS <<LOGINID::20070412>>
DOCUMENT NUMBER: 139:345909
TITLE: Use of angiotensin II inhibitors to prevent malignancies associated with immunosuppression
INVENTOR(S): Suthanthiran, Manikkam; Maluccio, Mary
PATENT ASSIGNEE(S): Cornell Research Foundation, Inc., USA
SOURCE: U.S., 7 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	---	-----	-----	-----
US 6641811	B1	20031104	US 2001-781146	20010209
US 2004067233	A1	20040408	US 2003-627408	20030725
PRIORITY APPLN. INFO.:			US 2000-181485P	P 20000210
			US 2001-781146	A3 20010209
REFERENCE COUNT:	18	THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT		

L9 ANSWER 8 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2002:849376 CAPLUS <<LOGINID::20070412>>
 DOCUMENT NUMBER: 137:358120
 TITLE: Compositions and methods for treating colorectal polyps and cancer
 INVENTOR(S): Tamura, Masaaki
 PATENT ASSIGNEE(S): Vanderbilt University, USA
 SOURCE: PCT Int. Appl., 143 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	---	-----	-----	-----
WO 2002087503	A2	20021107	WO 2002-US13383	20020426
WO 2002087503	A3	20031009		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2002311859	A1	20021111	AU 2002-311859	20020426
US 2003083339	A1	20030501	US 2002-133056	20020426
PRIORITY APPLN. INFO.:			US 2001-286621P	P 20010426
			WO 2002-US13383	W 20020426

L9 ANSWER 9 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2001:209554 CAPLUS <<LOGINID::20070412>>
 DOCUMENT NUMBER: 135:298256
 TITLE: Angiotensin II receptor blockade: a novel strategy to prevent immunosuppressant-associated cancer progression
 AUTHOR(S): Maluccio, M.; Sharma, V.; Lagman, M.; Konijn, G.; Suthanthiran, M.
 CORPORATE SOURCE: Department of Transplantation and Extracorporeal Therapy, Division of Nephrology, New York Presbyterian Hospital, Weill Medical College of Cornell University, New York, NY, USA
 SOURCE: Transplantation Proceedings (2001), 33(1-2), 1820-1821
 CODEN: TRPPA8; ISSN: 0041-1345
 PUBLISHER: Elsevier Science Inc.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> file pctfull
COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
33.30	43.86

FILE 'PCTFULL' ENTERED AT 12:54:54 ON 12 APR 2007
COPYRIGHT (C) 2007 Univentio

FILE LAST UPDATED:	10 APR 2007	<20070410/UP>
MOST RECENT UPDATE WEEK:	200714	<200714/EW>
FILE COVERS 1978 TO DATE		

>>> IMAGES ARE AVAILABLE ONLINE AND FOR EMAIL-PRINTS <<<

=> s captopril
3750 CAPTOPRIL
7 CAPTOPRILS
L10 3752 CAPTOPRIL
(CAPTOPRIL OR CAPTOPRILS)

=> s losartan
1805 LOSARTAN
1 LOSARTANS
L11 1805 LOSARTAN
(LOSARTAN OR LOSARTANS)

=> s l10 or l11
L12 4267 L10 OR L11

=> s cancer? or neoplas? or tumor? or carcinom?
87176 CANCER?
25305 NEOPLAS?
72460 TUMOR?
34117 CARCINOM?
L13 110137 CANCER? OR NEOPLAS? OR TUMOR? OR CARCINOM?

=> s l13 and l12
L14 2500 L13 AND L12

=> s l14 not py>1999
807628 PY>1999
L15 311 L14 NOT PY>1999

=> d ibib kwic

L15 ANSWER 1 OF 311 PCTFULL COPYRIGHT 2007 Univentio on STN
ACCESSION NUMBER: 2001062725 PCTFULL
no bibliographic data available - please use FPI for PI information
DESIGNATED STATES

DETD Both the growth and metastasis of solid tumors are also
angiogenesis-
dependent (Folkman, 1986, J. Cancer Res. 46:467-473; Folkman,
1989, J. Nat. Cancer
Inst. 82:4-6; Follmian et al. 1995, Tumor Angiogenesis,
Chapter 10, pp. 206-32, in
The Molecular Basis of Cancer, Mendelsohn et al., eds. (W. B.
Saunders). It has been
shown for example, that tumors which enlarge to greater than
about 2 mm in diameter
must obtain their own blood supply and do so by inducing the growth of
new capillary
blood vessels. After these new blood vessels become embedded in the
tumor, they

provide nutrients and growth factors essential for tumor growth as well as a means for I 0 tumor cells to enter the circulation and metastasize to distant sites, such as liver, lung or bone (W'cidner1991, New Eng. J. Med. 324(1):1-8). When used as drugs in tumor-bearing animals, natural inhibitors of angiogenesis can prevent the growth of small tumors (O'Reilly et al., 1994, Cell 79:315-328). Indeed, in some protocols, the application of such inhibitors leads to tumor regression and dormancy even after cessation of treatment (O'Reilly et al., 1997, Cell 88:277-285). Moreover, supplying inhibitors of angiogenesis to certain tumors can potentiate their response to other therapeutic regimens (e.g., chemotherapy) (see, e.g., Teischer et al., 1994, Int. J.

Cancer 57:920-925).

Although several angiogenesis inhibitors are currently under development for use in treating angiogenic diseases (Gasparini, 1996, Eur. J. Cancer 32A(14):2379-2385), there are disadvantages associated with these proposed inhibitory compounds. For example, suramin is a potent angiogenesis inhibitor, but, at doses required to.

inhibit angiogenesis within the tissue. In one aspect, the tissue is selected from the group consisting of eye tissue, skin tissue, a tumor, a tissue within a joint, bone marrow, nasal epithelium, prostate, ovarian and endometrial tissue. In a preferred embodiment, the tissue is eye.

The invention also includes a method of treating a benign neoplasia in a mammal, the method comprising administering PEDF to the mammal, thereby treating the benign-neoplasia. In one aspect, the benign neoplasia is a nasal polyp. In another aspect, the mammal is a human having cystic fibrosis. In yet a further aspect, the benign neoplasia is in the prostate gland.

The invention also includes a method of determining the severity of a tumor by assaying for the presence of PEDF within the tumor, wherein the absence of PEDF within the tumor indicates an advanced state and the presence of PEDF within the tumor indicates an early state of the tumor.

of images of photomicrographs of sections of skin obtained from animals treated with PEDF, wherein hair follicles are depicted. Human SK-N-BE(.2) neuroblastoma tumors growing subcutaneously in nude mice were injected at 2-3 sites/tumor for four consecutive days with 2 g of purified PEDF. On the fifth day, hair was

noticed
growing over the treated tumors. Histological sections (see
PEDF treated, Figures
8B and 8C) exhibited a three-fold increased density of hair follicles
compared with

6

skin overlying tumors treated with vehicle only (PBS-treated,
Figure 8A). Similar
increases in hair follicle density have been seen in the absence of
tumors following
injection of purified PEDF.

15 Figure 11, comprising Figures 11A-11E, is a series of
photomicrographs taken of human SK-N-BE(2) neuroblastoma
tumors growing in
nude mice that have been injected with the vehicle phosphate buffered
saline (PBS;
Figures 11A and 11B) or . . . fixed and stained for neurofilament
protein, an indicator of differentiation. Dramatically increased
staining and
therefore differentiation can be seen in the treated tumors.
In Figure 11C,
differentiation is clearly present along the needle track (clear
rectangle in upper
center) where the PEDF was injected.

activity of human
vitreal fluid and corneal extracts. Figure 12A: PEDF (0.1 g/ml)
purified from
WERI-Rb-27R. (Xu, et al., 1991, Cancer Res. 51:4881) medium
was tested alone or
in combination with antibody against recombinant PEDF (anti-EPC-1; 20
g/ml) or
against PEDF peptide (anti-PEDF; 1 g/ml) for its ability to inhibit the migration of
bovine capillary. . .

and WERI-Rb-1; all from American Type Culture Collection, Rockville,
Maryland) and from one Rb-positive line (WERI-Rb-27R) (Xu, et al., 1991,
Cancer
Res. 51:4881). Cells were maintained in nonoxia (N; 21% O₂), Hypoxia
(H; 05%
O₂), or COCICO (100 M), and serum-free media were collected over a 48-hour
period from equivalent numbers of cells. The blot. . .

neovascularization associated with several skin
diseases. For example, the inventive method is useful for treating
diseases and
disorders such as psoriasis, scleroderma, tumors of the skin,
neovascularization as a
consequence of infection (e.g., cat scratch disease, bacterial
ulceration, etc.) or other
skin disorders. Where PEDF. . .

In other embodiments, the tissue is a tumor (e.g., a benign or
cancerous
growth), in which case the inventive method will inhibit the growth of
blood vessels
within and to the tumor, and in some cases, induce
tumor cells to differentiate and thus
divide slowly. Inhibiting the growth of blood vessels within
tumors prevents sufficient
nutrients and oxygen from being supplied to the tumor to
support growth beyond a
given size. Thus, the inventive method can prevent the nucleation of

tumors from

cancerous cells already present due to genetic predisposition (e.g., BRCA-1 mutation carriers, Li Fraumeni patients with p53 mutations, etc.) or the presence of external carcinogens (e.g., tobacco, alcohol, industrial solvents, etc.). Aside from preventing

tumorigenesis, the inventive method can retard the growth of existing tumors, thus rendering them more easily contained and excised and may cause them to regress. This

application is highly advantageous for treating tumors that are difficult to operate on

(e.g., brain or prostate tumors). In addition, the method is useful for treatment of

childhood tumors, including, but not limited to, neuroblastoma. Moreover, minimizing

the number of blood vessels within existing tumors lessens the probability that the

tumor will metastasize. In treating tumors, the method can be used alone or in

conjunction with other treatments, to control the growth of tumors. Indeed, employing

the inventive method can potentiate the response of some tumors to other therapies.

in conjunction with agents which promote the differentiation of cells, particularly, but not limited to agents which promote the differentiation of brain

tumor cells.

useful for

treatment of nasal polyps, especially in cystic fibrosis patients, leukemia which stems

from bone marrow cell abnormal growth, and prostate cancer.

The invention can be

construed in general to be useful for treatment of benign neoplasias including those in the prostate.

PEDF may be used to prevent the onset

of diabetic retinopathy in a patient having diabetes, to prevent the onset of cancer in

persons known to be at risk for certain cancers, and the like.

Thus, the methods of the

invention should not be construed as being limited to treatment of overt disease.

tissue specific promoters (e.g., inducible and/or repressible promoters, such as a promoter responsive to TNF or RU486, the metallothionine promoter, etc.),

and tumor-specific promoters.

applied topically to the tissue of interest (e.g., injected, or pumped as a continuous infusion, or as a bolus within a tumor or intercutaneous or

subcutaneous site, applied to all or a portion of the surface of the skin, dropped onto the surface of.

invention should also be construed to include

the killing of cells by PEDF, particularly cells in existing vessels near or within a

tumor when activated by tumor angiogenesis factors.

Thus, within the context of the present invention, inhibition of angiogenesis should be construed to include inhibition of the development. . .

Because it is known that PEDF is reduced or absent from some tumors, the invention also provides a method of assessing the prognosis of a tumor by assaying for the presence of PEDF within the tumor. The method involves obtaining tissue or fluid from the tumor and detecting the presence or absence of PEDF within the tissue or fluid. The tissue or fluid may be, for example, urine, plasma, serum, or vitreous or aqueous humor. The greater the PEDF concentration within the tumor correlates with a lesser likelihood that the tumor is undergoing angiogenesis. Thus, a higher PEDF concentration within the tumor is indicative of a relatively early stage of tumorigenesis and is, therefore, an optimistic indication. Conversely, the absence of PEDF within a given tumor, or the presence of a low level of PEDF, is indicative of a more advanced stage of tumorigenesis. Higher or lower. . .

may be measured in immunological assays, PEDF purification assays or PAGE analysis, etc.). Reagents for detecting the presence of PEDF within such

tumors are known in the art (see, e.g., published international patent applications WO 95/33480 and WO 93/24529).

inhibits endothelial cell migration. These results are surprising, given that the PEDF protein is known to induce neural differentiation of cultured retinoblastoma tumor cells, to be a neurotrophic factor for cerebellar granular cells and a cytostatic factor for glial cells (Taniwaki et al., 1997, J. . . .

Table I

Agent ED50-(PM)

PEDF 0 0.5

Thrombospondin 0.5

Endostatin 3.0

Angiostatin 3.5

Retinoic Acid 1 5

Tissue Inhibitor of Metalloproteinase-1 3500

Captopril 1 Opo

1 0 Ex]mple 4

These data demonstrate that PEDF inhibits the angiogenic activity of known angiogenic agents.

These data also differentiate the region of PEDF that is anti-angiogenic from the region which induces differentiation in retinoblastoma tumor cells and that which is neurotrophic. It has been shown by (Alberdi et al., 1999, J. Biol. Chem.

follicles (pilo sebaceous gland). An increase in hair follicle density was

15 observed in the skin overlying experimentally produced neuroblastoma tumors that were injected daily for four consecutive days with purified PEDF. This was not observed in the skin of control animals whose tumors were similarly injected with saline vehicle.

of 2 μ g of purified histidine-tagged PEDF in a volume of 100 μ l of phosphate buffered saline into 2-3 sites/tumor each day for 4 consecutive days. On the fifth day, a small area of increased hair growth was noticed over the injection sites. The mice were euthanized using an overdose of metaphane, and the tumors were surgically removed. Tumor tissue was sliced and placed in buffered formalin for at least 24 hours. Tissue was embedded in paraffin and prepared for histologic examination. The skin overlying neuroblastoma tumors treated with PEDF had increased hair follicle density when compared with the skin overlying tumors injected with saline vehicle (Figure 8). Similar increases in hair follicle density have been seen in the absence of tumors following injection of purified PEDF.

Example 8

The data presented herein depict the fact that PEDF triggers differentiation of neuroblastoma tumors, thereby providing the basis for treatment of these tumors. In vitro treatment of neuroblastoma cells, and in vivo treatment of experimentally produced neuroblastoma tumors with purified histidine tagged-PEDF protein triggered differentiation of the cells. These data therefore suggest that administration of PEDF to these cells is an effective means for induce these tumors to differentiate and therefore grow more slowly.

PEDF is a protein expressed and secreted by many cell types including Schwann cells. Neuroblastomas are malignant tumors, and the presence of Schwann cells within these tumors is associated with better outcomes. The data presented herein indicate that one of the reasons the presence of Schwann cells leads to a favorable prognosis for neuroblastoma tumors is the fact that these cells produce PEDF. The PEDF produced therein acts in a paracrine fashion on the tumor cells to induce their differentiation. Since differentiated neuroblastoma cells grow more slowly, if at all, the administration of PEDF to neuroblastoma tumors provides a novel therapy for this tumor by slowing the growth of the cells. Cell growth is slowed in two ways, (1) by binding of PEDF to endothelial cells that form the blood vessels feeding the tumor and preventing their growth and thereby indirectly inhibiting the tumor, and (2) by binding

of PEDF directly to the tumor cells thereby inducing their differentiation.

In vitro experiments were conducted to verify the effect of PEDF on cell lines derived from neuroblastoma tumors. Two neuroblastoma derived cell lines were obtained from the American Tissue Type and Culture, SK-N-BE(2) and SK-N-SH.

In vivo experiments were conducted to determine the effect of PEDF on neuroblastoma tumors. Human neuroblastomas were experimentally induced in X 106 athymic (nu/nu) mice by injecting I SK-N-BE(2) cells subcutaneously into 2 sites on the hind flanks of each mouse. When the tumors grew to a palpable size I 0 (approximately 8 mm in diameter) PEDF treatment was started. A total of 2 Ptg of purified histidine-tagged PEDF in a volume of 100 µl of phosphate buffered saline was injected into 2-3 sites/tumor each day for 4 consecutive days. On the fifth day, the mice were euthanized by an overdose of metaphane, and the tumors were surgically removed. Tumor tissue was sliced and placed in buffered formalin for at least 24 hours. Tissue was embedded in paraffin and.

Sections were stained with an antibody that recognized neurofilament protein (Dako, Carpinteria, CA). Neuroblastoma tumors treated with PEDF exhibited increased differentiation as determined by acquisition of positive staining for neurofilament protein (Figure 1). A total of six SK-N-BE(2) tumors were treated with PEDF and 6/6 were moderately to strongly positive for neurofilament staining. A total of 4 tumors were treated with PBS and all were negative or exhibit focal staining of single cells with more abundant cytoplasm (Figure I).

regulation in most healthy tissues where the influence of naturally occurring inhibitors prevents new vessel growth (Bouck et al., 1996, Adv. Cancer 69:135; Hanahan and Folkman, 1996, Cell 86:353). The disruption of such controls plays an essential role in the development of a variety of diseases, from arthritis to cancer (Folkman et al., 1995, Molecular Basis of Cancer 206-232). In the healthy mammalian eye, vessels are normally excluded from the cornea and from the vitreous, both compartments that have been.

In studies aimed at identifying antiangiogenic factors in the eye that might be regulated by the retinoblastoma tumor suppressor gene (Rb), media was fractionated where the media was previously conditioned by a retinoblastoma cell line that had been infected with a retrovirus expressing the wild-type Rb gene, WERI-Rb-27R. (Xu et al., 1991, Cancer Res. 51:448 1). A protein

purification scheme resulted in a 1000- to 1250-fold enrichment of antiangiogenic activity and a single 50-kD. . . (Pharmacia) with 0.5 M α -methyl-D-mannopyranoside, and elution from a HiTrap heparin Sepharose column (Pharmacia) with increasing NACI gradient. (Xu, et al., 1991, Cancer Res. 51:4481). Purification was monitored by an endothelial cell migration assay, and the yield was 17.5%. Migration assays were performed in quadruplicate. . .

To further investigate the effect of oxygen regulation on PEDF, retinoblastoma tumor cells were maintained in low oxygen (0.5%) or in chemical agents that simulate hypoxia (Goldberg, et al., 1988, Science 242:1214). As. . .

Medium conditioned by hypoxic tumor cells was more angiogenic than that conditioned by normoxic tumor cells (Figure 15C). Hypoxia reduced the concentration of medium needed to induce 50% of maximal endothelial cell chemotaxis from 4.0 to 0.3. . . angiogenic activity of these cells, did not reduce the angiogenic activity of the hypoxic conditioned media, but neutralization of PEDF made normoxic tumor media as angiogenic as that derived from hypoxic cells.

(Figure 15C). Consistent with these in vitro studies, tumor cells present in 12 out of 12 human retinoblastoma pathologic specimens failed to stain for PEDF, presumably in part because of limited oxygen in the tumor environment (Gulledge and Dewhirst, 1996, Anticancer Res. 16:741), whereas adjacent normal retina was positive.

of blood vessel growth in the eye by creating a permissive environment for angiogenesis When oxygen is limiting (as it is in tumors and in retinopathics) and an inhibitory environment when oxygen concentrations are normal or high. Given its high potency and the broad range. . .

CLMEN. . . 5 The method of claim 4, wherein said tissue is selected from the group consisting of eye tissue, skin tissue, a tumor, a tissue within a joint, bone marrow, nasal epithelium, prostate, ovarian and endometrial tissue.

for said PEDF to inhibit angiogenesis in said eye, thereby treating said macular degeneration. I 1. A method of treating a benign neoplasia in a mammal, said method comprising administering PEDF to said mammal, thereby treating said benign neoplasia.

12 The method of claim 1 1, wherein said benign neoplasia is a nasal polyp.

14 The method of claim I 1, wherein said benign neoplasia is
in the
prostate gland.

fragment

of PEDF comprises amino acids 44-77 of SEQ ID NO: 1.

3 8. A method of determining the severity of a tumor by
assaying for the
presence of PEDF within the tumor, wherein the absence of PEDF
within the tumor
indicates an advanced state and the presence of PEDF within the
tumor indicates an
early state of the tumor.

=> d his

(FILE 'HOME' ENTERED AT 12:51:41 ON 12 APR 2007)

FILE 'REGISTRY' ENTERED AT 12:51:46 ON 12 APR 2007

 E "CAPTOPRIL"/CN 25
L1 1 S E3
 E "LOSARTAN"/CN 25
L2 1 S E3

FILE 'CAPLUS' ENTERED AT 12:52:31 ON 12 APR 2007

L3 2324 S L1/THU
L4 1975 S L2/THU
L5 788148 S CANCER? OR NEOPLAS? OR TUMOR? OR CARCINOM?
L6 26 S L3 (L) L5
L7 8 S L6 NOT PY>2000
L8 4 S L7 AND HUMAN
L9 10 S L4 (L) L5

FILE 'PCTFULL' ENTERED AT 12:54:54 ON 12 APR 2007

L10 3752 S CAPTOPRIL
L11 1805 S LOSARTAN
L12 4267 S L10 OR L11
L13 110137 S CANCER? OR NEOPLAS? OR TUMOR? OR CARCINOM?
L14 2500 S L13 AND L12
L15 311 S L14 NOT PY>1999

=> s 115 and human

 228055 HUMAN
 89732 HUMANS
 238084 HUMAN
 (HUMAN OR HUMANS)

L16 280 L15 AND HUMAN

=> s 110/ab

L17 24 (CAPTOPRIL/AB)

=> s 111/ab

 39 LOSARTAN/AB
 1 LOSARTANS/AB
L18 39 (LOSARTAN/AB)
 ((LOSARTAN OR LOSARTANS)/AB)

=> s 110/clm

L19 633 (CAPTOPRIL/CLM)

=> s 111/clm

L20 362 (LOSARTAN/CLM)

=> s 15/clm
 25411 CANCER?/CLM
 4141 NEOPLAS?/CLM
 16849 TUMOR?/CLM
 4957 CARCINOM?/CLM
 L21 36455 (CANCER?/CLM OR NEOPLAS?/CLM OR TUMOR?/CLM OR CARCINOM?/CLM)

=> s 117 or 118 or 119 or 120
 L22 801 L17 OR L18 OR L19 OR L20

=> s 122 and 121
 L23 217 L22 AND L21

=> s 123 not py>1999
 807628 PY>1999
 L24 16 L23 NOT PY>1999

=> d ibib 1-5

L24 ANSWER 1 OF 16 PCTFULL COPYRIGHT 2007 Univentio on STN
 ACCESSION NUMBER: 1999043663 PCTFULL ED 20020515 <<LOGINID::20070412>>
 TITLE (ENGLISH): N-[(SUBSTITUTED FIVE-MEMBERED DI- OR TRIAZA
 DIUNSATURATED RING)CARBONYL] GUANIDINE DERIVATIVES FOR
 THE TREATMENT OF ISCHEMIA
 TITLE (FRENCH): DERIVES DE LA N-[(A CYCLE DI OU TRIAZA DIINSATURE
 SUBSTITUE) CARBONYLE] GUANIDINE UTILISES POUR LE
 TRAITEMENT DE L'ISCHEMIE
 INVENTOR(S): HAMANAKA, Ernest, S.;
 GUZMAN-PEREZ, Angel;
 RUGGERI, Roger, B.;
 WESTER, Ronald, T.;
 PATENT ASSIGNEE(S): MULARSKI, Christian, J.
 PFIZER PRODUCTS INC.;
 HAMANAKA, Ernest, S.;
 GUZMAN-PEREZ, Angel;
 RUGGERI, Roger, B.;
 WESTER, Ronald, T.;
 MULARSKI, Christian, J.
 LANGUAGE OF PUBL.: English
 DOCUMENT TYPE: Patent
 PATENT INFORMATION:

NUMBER	KIND	DATE
WO 9943663	A1	19990902

DESIGNATED STATES
 W:

AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE
 ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR
 KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT
 RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU
 ZW GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ
 TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT
 SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

PRIORITY INFO.: US 1998-60/076,362 19980227
 APPLICATION INFO.: WO 1999-IB206 A 19990205

L24 ANSWER 2 OF 16 PCTFULL COPYRIGHT 2007 Univentio on STN
 ACCESSION NUMBER: 1999030690 PCTFULL ED 20020515 <<LOGINID::20070412>>
 TITLE (ENGLISH): ORAL DELIVERY FORMULATION
 TITLE (FRENCH): FORMULATION D'ADMINISTRATION PAR VOIE ORALE
 INVENTOR(S): COMPTON, Bruce, Jon;
 SOLARI, Nancy, E.;
 FLANAGAN, Margaret, A.
 PATENT ASSIGNEE(S): AXIA THERAPEUTICS, INC.;
 COMPTON, Bruce, Jon;

LANGUAGE OF PUBL.: SOLARI, Nancy, E.;
DOCUMENT TYPE: FLANAGAN, Margaret, A.
PATENT INFORMATION: English
Patent

	NUMBER	KIND	DATE
	WO 9930690	A1	19990624
DESIGNATED STATES			
W:	AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG		
PRIORITY INFO.:	US 1997-60/069,501		19971215
	US 1998-60/073,867		19980204
	US 1998-09/055,163		19980404
	US 1998-09/055,560		19980406
APPLICATION INFO.:	WO 1998-US26627	A	19981215

L24 ANSWER 3 OF 16 PCTFULL COPYRIGHT 2007 Univentio on STN
ACCESSION NUMBER: 1999018956 PCTFULL ED 20020515 <<LOGINID::20070412>>
TITLE (ENGLISH): 12(S)-HETE RECEPTOR BLOCKERS
TITLE (FRENCH): INHIBITEURS DU RECEPTEUR DE 12(S)-HETE
INVENTOR(S): NATARAJAN, Rama, Devi;
NADLER, Jerry, L.
PATENT ASSIGNEE(S): CITY OF HOPE
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

	NUMBER	KIND	DATE
	WO 9918956	A1	19990422
DESIGNATED STATES			
W:	AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG		
PRIORITY INFO.:	US 1997-60/062,335		19971015
APPLICATION INFO.:	WO 1998-US21570	A	19981014

L24 ANSWER 4 OF 16 PCTFULL COPYRIGHT 2007 Univentio on STN
ACCESSION NUMBER: 1999008596 PCTFULL ED 20020515 <<LOGINID::20070412>>
TITLE (ENGLISH): MEASUREMENT OF CAPILLARY RELATED INTERSTITIAL FLUID
USING ULTRASOUND METHODS AND DEVICES
TITLE (FRENCH): MESURE DU FLUIDE INTERSTITIEL PROPRE AUX CAPILLAIRES
UTILISANT DES METHODES ET DES DISPOSITIFS
ECHOGRAPHIQUES
INVENTOR(S): LANG, Philipp;
MENDLEIN, John, D.
PATENT ASSIGNEE(S): LANG, Philipp;
MENDLEIN, John, D.
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

	NUMBER	KIND	DATE
	WO 9908596	A1	19990225
DESIGNATED STATES			

W: AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE
ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC
LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU
SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW GH
GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT
BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF
BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

PRIORITY INFO.: US 1997-08/914,527 19970819
APPLICATION INFO.: WO 1998-US17238 A 19980819

L24 ANSWER 5 OF 16 PCTFULL COPYRIGHT 2007 Univentio on STN
ACCESSION NUMBER: 1998051282 PCTFULL ED 20020514 <<LOGINID::20070412>>
TITLE (ENGLISH): SOLID POROUS MATRICES AND METHODS OF MAKING AND USING
THE SAME
TITLE (FRENCH): MATRICES POREUSES SOLIDES, LEUR PROCEDE DE FABRICATION
ET LEUR UTILISATION
INVENTOR(S): UNGER, Evan, C.
PATENT ASSIGNEE(S): IMARX PHARMACEUTICAL CORP.
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

NUMBER	KIND	DATE
WO 9851282	A1	19981119

DESIGNATED STATES
W: AU BR CA CN JP KR NZ AT BE CH CY DE DK ES FI FR GB GR
IE IT LU MC NL PT SE

PRIORITY INFO.: US 1997-60/046,379 19970513
US 1998-9/075,477 19980511
APPLICATION INFO.: WO 1998-US9570 A 19980512

=> d ibib 6-10

L24 ANSWER 6 OF 16 PCTFULL COPYRIGHT 2007 Univentio on STN
ACCESSION NUMBER: 1998036784 PCTFULL ED 20020514 <<LOGINID::20070412>>
TITLE (ENGLISH): COATED IMPLANTABLE MEDICAL DEVICE
TITLE (FRENCH): DISPOSITIF MEDICAL IMPLANTABLE DOTE D'UN REVETEMENT
INVENTOR(S): RAGHEB, Anthony, O.;
BATES, Brian, L.;
FEARNOT, Neal, E.;
KOZMA, Thomas, G.;
VOORHEES, William, D., III;
GERSHLICK, Anthony, H.
PATENT ASSIGNEE(S): COOK INCORPORATED
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

NUMBER	KIND	DATE
WO 9836784	A1	19980827

DESIGNATED STATES
W: AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE
ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC
LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU
SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW GH GM
KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE
CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF
CG CI CM GA GN ML MR NE SN TD TG

PRIORITY INFO.: US 1997-60/038,459 19970220
APPLICATION INFO.: WO 1998-US3438 A 19980220

L24 ANSWER 7 OF 16 PCTFULL COPYRIGHT 2007 Univentio on STN
ACCESSION NUMBER: 1998032718 PCTFULL ED 20020514 <<LOGINID::20070412>>

TITLE (ENGLISH): NEW FATTY ACID DERIVATIVES
TITLE (FRENCH): NOUVEAUX DERIVES D'ACIDE GRAS
INVENTOR(S): MYHREN, Finn;

BORRETZEN, Bernt;
DALEN, Are;
SANDVOLD, Marit, Liland
PATENT ASSIGNEE(S): NORSK HYDRO ASA;
MYHREN, Finn;
BORRETZEN, Bernt;
DALEN, Are;
SANDVOLD, Marit, Liland

LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent

PATENT INFORMATION:

NUMBER	KIND	DATE
--------	------	------

WO 9832718	A1	19980730
------------	----	----------

DESIGNATED STATES

W:

AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE
ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC
LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU
SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW GH
GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT
BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ
CF CG CI CM GA GN ML MR NE SN TD TG

PRIORITY INFO.: GB 1997-9701441.9 19970124

APPLICATION INFO.: WO 1998-NO21 A 19980123

L24 ANSWER 8 OF 16

ACCESSION NUMBER: 1998032022 PCTFULL ED 20020514 <<LOGINID::20070412>>

TITLE (ENGLISH): GROWTH FACTOR-DEPENDENT DISEASES

TITLE (FRENCH): MALADIES LIEES AU FACTEUR DE CROISSANCE

INVENTOR(S): EPSTEIN, Richard, John

PATENT ASSIGNEE(S): IMPERIAL EXPLOITATION LIMITED;

EPSTEIN, Richard, John

LANGUAGE OF PUBL.: English

DOCUMENT TYPE: Patent

PATENT INFORMATION:

NUMBER	KIND	DATE
--------	------	------

WO 9832022	A1	19980723
------------	----	----------

DESIGNATED STATES

W:

JP US AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT
SE

PRIORITY INFO.: GB 1997-9700933.6 19970117

APPLICATION INFO.: WO 1998-GB33 A 19980115

L24 ANSWER 9 OF 16

ACCESSION NUMBER: 1998018610 PCTFUL ED 20020514 <<LOGINID::20070412>>

TITLE (ENGLISH): EMBEDDING AND ENCAPSULATION OF CONTROLLED RELEASE

PARTICLES

TITLE (FRENCH): INCLUSION ET ENCAPSULATION DE PARTICULES A LIBERATION

CONTROLEE

INVENTOR(S): VAN LENGERICH, Bernhard, H.

PATENT ASSIGNEE(S): VAN LENGERICH, Bernhard, H.

LANGUAGE OF PUBL.: English

DOCUMENT TYPE: Patent

PATENT INFORMATION:

NUMBER	KIND	DATE
--------	------	------

WO 9818610	A1	19980507
------------	----	----------

DESIGNATED STATES

W:

AU CA JP NO PL US AT BE CH DE DK ES FI FR GB GR IE IT
LU MC NL PT SE

PRIORITY INFO.: US 1996-60/029,038 19961028
US 1997-60/052,717 19970716
APPLICATION INFO.: WO 1997-US18984 A 19971027

L24 ANSWER 10 OF 16 PCTFULL COPYRIGHT 2007 Univentio on STN
ACCESSION NUMBER: 1998017331 PCTFULL ED 20020514 <<LOGINID::20070412>>
TITLE (ENGLISH): SILVER IMPLANTABLE MEDICAL DEVICE
TITLE (FRENCH): DISPOSITIF MEDICAL IMPLANTABLE ET CONTENANT DE L'ARGENT
INVENTOR(S): BATES, Brian, L.;
OSBORNE, Thomas, A.;
ROBERTS, Joseph, W.;
FEARNOT, Neal, E.;
KOZMA, Thomas, G.;
RAGHEB, Anthony, O.;
VOORHEES, William, D., III
PATENT ASSIGNEE(S): COOK INCORPORATED;
MED INSTITUTE, INC.
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

NUMBER	KIND	DATE
WO 9817331	A1	19980430

DESIGNATED STATES
W:

AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE
ES FI GB GE GH HU IL IS JP KE KG KP KR KZ LC LK LR LS
LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG
SI SK SL TJ TM TR TT UA UG UZ VN YU ZW GH KE LS MW SD
SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES
FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA
GN ML MR NE SN TD TG

PRIORITY INFO.: US 1996-60/029,158 19961024
US 1996-8/741,565 19961031
US 1997-8/803,843 19970224
APPLICATION INFO.: WO 1997-US19188 A 19971023

=> d ibib 11-16

L24 ANSWER 11 OF 16 PCTFULL COPYRIGHT 2007 Univentio on STN
ACCESSION NUMBER: 1998015574 PCTFULL ED 20020514 <<LOGINID::20070412>>
TITLE (ENGLISH): METHODS AND COMPOSITIONS FOR GENERATING ANGIOSTATIN
TITLE (FRENCH): PROCEDES ET COMPOSITIONS DESTINES A PRODUIRE DE
L'ANGIOSTATINE
INVENTOR(S): SOFF, Gerald;
GATELY, Stephen, T.;
TWARDOWSKI, Przemyslaw
PATENT ASSIGNEE(S): NORTHWESTERN UNIVERSITY;
SOFF, Gerald;
GATELY, Stephen, T.;
TWARDOWSKI, Przemyslaw
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

NUMBER	KIND	DATE
WO 9815574	A1	19980416

DESIGNATED STATES
W:

AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE
ES FI GB GE GH HU ID IL IS JP KE KG KP KR KZ LC LK LR
LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE
SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW GH KE LS
MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH DE
DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI

	CM GA GN ML MR NE SN TD TG
PRIORITY INFO.:	US 1996-8/710,305 19960917
APPLICATION INFO.:	WO 1997-US16539 A 19970917

L24 ANSWER 12 OF 16 PCTFULL COPYRIGHT 2007 Univentio on STN

ACCESSION NUMBER: 1997031654 PCTFULL ED 20020514 <<LOGINID::20070412>>

TITLE (ENGLISH): NITRIC OXIDE DONORS CAPABLE OF REDUCING TOXICITY FROM DRUGS

TITLE (FRENCH): DONNEURS D'OXYDE NITRIQUE CAPABLES DE DIMINUER LA TOXICITE DE MEDICAMENTS

INVENTOR(S): DEL SOLDATO, Piero

PATENT ASSIGNEE(S): NICOX S.A.;
DEL SOLDATO, Piero

LANGUAGE OF PUBL.: English

DOCUMENT TYPE: Patent

PATENT INFORMATION:

NUMBER	KIND	DATE

WO 9731654	A1	19970904

DESIGNATED STATES

W:

AL AU BB BG BR CA CN CZ EE GE HU IL IS JP KP KR LK LR
LT LV MG MK MN MX NO NZ PL RO RU SG SI SK TR TT UA US
UZ VN KE LS MW SD SZ UG AM AZ BY KG KZ MD RU TJ TM AT
BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ
CF CG CI CM GA GN ML MR NE SN TD TG

PRIORITY INFO.:	IT 1996-MI96A000352 19960226
APPLICATION INFO.:	WO 1997-EP873 A 19970224

L24 ANSWER 13 OF 16 PCTFULL COPYRIGHT 2007 Univentio on STN

ACCESSION NUMBER: 1995018603 PCTFULL ED 20020514 <<LOGINID::20070412>>

TITLE (ENGLISH): TRANSDERMAL DEVICE CONTAINING POLYVINYLPYRROLIDONE AS SOLUBILITY ENHANCER

TITLE (FRENCH): DISPOSITIF D'ADMINISTRATION TRANSDERMIQUE CONTENANT DE LA POLYVINYLPYRROLIDONE EN TANT QU'AMPLIFICATEUR DE SOLUBILITE

INVENTOR(S): MIRANDA, Jesus;
SABLOTSKY, Steven

PATENT ASSIGNEE(S): NOVEN PHARMACEUTICALS, INC.;
MIRANDA, Jesus;
SABLOTSKY, Steven

LANGUAGE OF PUBL.: English

DOCUMENT TYPE: Patent

PATENT INFORMATION:

NUMBER	KIND	DATE

WO 9518603	A1	19950713

DESIGNATED STATES

W:

AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE
HU JP KE KG KP KR KZ LK LR LT LU LV MD MG MN MW MX NL
NO NZ PL PT RO RU SD SE SI SK TJ TT UA US UZ VN KE MW
SD SZ AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE
BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

PRIORITY INFO.:	US 1994-8/178,558 19940107
APPLICATION INFO.:	WO 1995-US22 A 19950109

L24 ANSWER 14 OF 16 PCTFULL COPYRIGHT 2007 Univentio on STN

ACCESSION NUMBER: 1993024154 PCTFULL ED 20020513 <<LOGINID::20070412>>

TITLE (ENGLISH): BIODEGRADABLE CONTROLLED RELEASE MELT-SPUN DELIVERY SYSTEM

TITLE (FRENCH): SYSTEME DE LIBERATION CONTROLEE BIODEGRADABLE FILE EN FUSION

INVENTOR(S): FUISZ, Richard, C.

PATENT ASSIGNEE(S): FUISZ TECHNOLOGIES, LTD.;
FUISZ, Richard, C.

LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

NUMBER	KIND	DATE

WO 9324154	A1	19931209

DESIGNATED STATES

W: AU CA HU JP KR PL US AT BE CH DE DK ES FR GB GR IE IT
LU MC NL PT SE

PRIORITY INFO.: US 1992-7/893,238 19920603
APPLICATION INFO.: WO 1993-US5307 A 19930602

L24 ANSWER 15 OF 16 PCTFULL COPYRIGHT 2007 Univentio on STN
ACCESSION NUMBER: 1991016882 PCTFULL ED 20020513 <<LOGINID::20070412>>
TITLE (ENGLISH): DIRECT SPRAY-DRIED DRUG/LIPID POWDER COMPOSITION
TITLE (FRENCH): COMPOSITION DE MEDICAMENT/LIPIDES EN POUDRE SECHEE PAR
PULVERISATION DIRECTE

INVENTOR(S): DURRANI, Manzer;
FITCH, Wendy;
FOK, Katherine;
RADHAKRISHNAN, Ramachandran;
USTER, Paul, S.

PATENT ASSIGNEE(S): LIPOSOME TECHNOLOGY, INC.

LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent

PATENT INFORMATION:

NUMBER	KIND	DATE

WO 9116882	A1	19911114

DESIGNATED STATES

W: AT AU BE CA CH DE DK ES FR GB GR IT JP LU NL SE

PRIORITY INFO.: US 1990-520,792 19900508
APPLICATION INFO.: WO 1991-US3092 A 19910506

L24 ANSWER 16 OF 16 PCTFULL COPYRIGHT 2007 Univentio on STN
ACCESSION NUMBER: 1990006775 PCTFULL ED 20020513 <<LOGINID::20070412>>
TITLE (ENGLISH): A NOVEL NONPHOSPHOLIPID LIPOSOME COMPOSITION FOR
SUSTAINED RELEASE OF DRUGS
TITLE (FRENCH): NOUVELLE COMPOSITION DE LIPOSOMES NON PHOSPHOLIPIDIQUE
A LIBERATION SOUTENUE DE MEDICAMENTS

INVENTOR(S): RADHAKRISHNAN, Ramachandran

PATENT ASSIGNEE(S): LIPOSOME TECHNOLOGY, INC.

LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent

PATENT INFORMATION:

NUMBER	KIND	DATE

WO 9006775	A1	19900628

DESIGNATED STATES

W: AT AU BE CH DE DK ES FI FR GB IT JP LU NL NO SE

PRIORITY INFO.: US 1988-284,158 19881214
US 1988-284,216 19881214
US 1989-Not furnished 19891201
APPLICATION INFO.: WO 1989-US5525 A 19891206

=>

---Logging off of STN---

=>

Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

30.29

74.15

STN INTERNATIONAL LOGOFF AT 12:59:14 ON 12 APR 2007

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1642BJF

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 "Ask CAS" for self-help around the clock
NEWS 3 DEC 18 CA/CAPLUS pre-1967 chemical substance index entries enhanced
with preparation role
NEWS 4 DEC 18 CA/CAPLUS patent kind codes updated
NEWS 5 DEC 18 MARPAT to CA/CAPLUS accession number crossover limit increased
to 50,000
NEWS 6 DEC 18 MEDLINE updated in preparation for 2007 reload
NEWS 7 DEC 27 CA/CAPLUS enhanced with more pre-1907 records
NEWS 8 JAN 08 CHEMLIST enhanced with New Zealand Inventory of Chemicals
NEWS 9 JAN 16 CA/CAPLUS Company Name Thesaurus enhanced and reloaded
NEWS 10 JAN 16 IPC version 2007.01 thesaurus available on STN
NEWS 11 JAN 16 WPIDS/WPINDEX/WPIX enhanced with IPC 8 reclassification data
NEWS 12 JAN 22 CA/CAPLUS updated with revised CAS roles
NEWS 13 JAN 22 CA/CAPLUS enhanced with patent applications from India
NEWS 14 JAN 29 PHAR reloaded with new search and display fields
NEWS 15 JAN 29 CAS Registry Number crossover limit increased to 300,000 in
multiple databases
NEWS 16 FEB 15 PATDPASPC enhanced with Drug Approval numbers
NEWS 17 FEB 15 RUSSIAPAT enhanced with pre-1994 records
NEWS 18 FEB 23 KOREAPAT enhanced with IPC 8 features and functionality
NEWS 19 FEB 26 MEDLINE reloaded with enhancements
NEWS 20 FEB 26 EMBASE enhanced with Clinical Trial Number field
NEWS 21 FEB 26 TOXCENTER enhanced with reloaded MEDLINE
NEWS 22 FEB 26 IFICDB/IFIPAT/IFIUDB reloaded with enhancements
NEWS 23 FEB 26 CAS Registry Number crossover limit increased from 10,000
to 300,000 in multiple databases
NEWS 24 MAR 15 WPIDS/WPIX enhanced with new FRAGHITSTR display format
NEWS 25 MAR 16 CASREACT coverage extended
NEWS 26 MAR 20 MARPAT now updated daily
NEWS 27 MAR 22 LWPI reloaded
NEWS 28 MAR 30 RDISCLOSURE reloaded with enhancements
NEWS 29 MAR 30 INPADOCDB will replace INPADOC on STN
NEWS 30 APR 02 JICST-EPLUS removed from database clusters and STN

NEWS EXPRESS NOVEMBER 10 CURRENT WINDOWS VERSION IS V8.01c, CURRENT
MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),